Nicholas Company Inc. Boosts Holdings in Certara, Inc. (NASDAQ:CERT)

Nicholas Company Inc. raised its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 47.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 558,888 shares of the company's stock after buying an additional 181,008 shares during the quarter. Nicholas Company Inc. owned approximately 0.35% of Certara worth $5,952,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. ANTIPODES PARTNERS Ltd raised its position in Certara by 204.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock valued at $58,000 after purchasing an additional 3,656 shares during the last quarter. HighTower Advisors LLC increased its stake in Certara by 647.2% in the fourth quarter. HighTower Advisors LLC now owns 146,539 shares of the company's stock valued at $1,561,000 after purchasing an additional 126,927 shares during the period. Amundi raised its holdings in shares of Certara by 222.8% in the fourth quarter. Amundi now owns 62,167 shares of the company's stock valued at $685,000 after buying an additional 42,907 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Certara by 188.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 20,797 shares of the company's stock worth $221,000 after buying an additional 13,592 shares during the period. Finally, Edgestream Partners L.P. boosted its stake in shares of Certara by 140.3% during the fourth quarter. Edgestream Partners L.P. now owns 365,708 shares of the company's stock worth $3,895,000 after buying an additional 213,549 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several analysts have commented on CERT shares. William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Barclays boosted their target price on Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. TD Cowen started coverage on Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price target for the company. Finally, Stephens reaffirmed an "overweight" rating and set a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Certara has an average rating of "Moderate Buy" and a consensus price target of $15.83.

Certara Price Performance

Shares of CERT traded down $0.09 on Thursday, reaching $10.60. The stock had a trading volume of 887,551 shares, compared to its average volume of 1,002,742. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.18. The firm has a market capitalization of $1.71 billion, a PE ratio of -53.00, a PEG ratio of 9.29 and a beta of 1.60. The firm has a 50-day moving average of $12.55 and a 200 day moving average of $11.51. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.